Ropinirole treatment for restless legs syndrome

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 4, 2008, Pages 611-623

  Bogan, Richard K ^a  

^a SleepMed of South Carolina   (United States)

Author keywords

Dopamine agonist; Restless legs syndrome; Ropinirole

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; FERRITIN; IRON; LEVODOPA; MUSCARINIC RECEPTOR; OPIATE RECEPTOR; PLACEBO; ROPINIROLE; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; TYROSINE 3 MONOOXYGENASE; DOPAMINE RECEPTOR STIMULATING AGENT; INDOLE DERIVATIVE;

ALCOHOL ABSTINENCE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOPAMINERGIC SYSTEM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; FATIGUE; FERRITIN BLOOD LEVEL; GENETIC SUSCEPTIBILITY; HEADACHE; HUMAN; INSOMNIA; IRON BLOOD LEVEL; IRON DEFICIENCY; MASSAGE; NAUSEA; NONHUMAN; PARKINSON DISEASE; POLYSOMNOGRAPHY; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SLEEP DISORDER; SLEEP THERAPY; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VOMITING; DRUG EFFECT; EVIDENCE BASED MEDICINE; MOTOR ACTIVITY; PATHOPHYSIOLOGY; REVIEW; SLEEP; TREATMENT OUTCOME;

DOPAMINE AGONISTS; EVIDENCE-BASED MEDICINE; HUMANS; INDOLES; MOTOR ACTIVITY; RESTLESS LEGS SYNDROME; SLEEP; TREATMENT OUTCOME;

EID: 40649127200     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.4.611     Document Type: Article

References (85)

1. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4(2):101-9
2. Rothdach AJ, Trenkwalder C, Haberstock J, et al. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology 2000;54(5):1064-8
3. Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001;16(6):1159-63
4. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002;53(1):547-54
5. Berger K, Luedemann J, Trenkwalder C, et al. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004;164(2):196-202
6. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165(11):1286-92
7. Tison F, Crochard A, Leger D, et al. Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology 2005;65(2):239-46
8. Wenning GK, Kiechl S, Seppi K, et al. Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. Lancet Neurol 2005;4(12):815-20
9. Hogl B, Kiechl S, Willeit J, et al. Restless legs syndrome: a community-based study of prevalence, severity and risk factors. Neurology 2005;64(11):1920-4
10. Tan EK, Seah A, See SJ, et al. Restless legs syndrome in an Asian population: a study in Singapore. Mov Disord 2001;16(3):577-9
11. Hening W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004;5(3):237-46
12. Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004;26(6):925-35
13. Kushida C, Martin M, Nikam P, et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res 2007;16(4):617-24
14. Kushida CA, Allen RP, Atkinson MJ. Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS. Sleep Med 2004;5(5):485-8
15. Montplaisir J, Boucher S, Poirier G, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997;12(1):61-5
16. Hornyak M, Feige B, Riemann D, Voderholzer U. Periodic leg movements in sleep and periodic limb movement disorder: prevalence, clinical significance and treatment. Sleep Med Rev 2006;10(3):169-77
17. Harsh J, Peszka J, Hartwig G, Mitler M. Night-time sleep and daytime sleepiness in narcolepsy. J Sleep Res 2000;9(3):309-16
18. Fantini ML, Michaud M, Gosselin N, et al. Periodic leg movements in REM sleep behavior disorder and related autonomic and EEG activation. Neurology 2002;59(12):1889-94
19. Warnes H, Dinner DS, Kotagal P, Burgess RC. Periodic limb movements and sleep apnoea. J Sleep Res 1993;2(1):38-44
20. Provini F, Vetrugno R, Meletti S, et al. Motor pattern of periodic limb movements during sleep. Neurology 2001;57(2):300-4
21. Gigli GL, Adorati M, Dolso P, et al. Restless legs syndrome in end-stage renal disease. Sleep Med 2004;5(3):309-15
22. Manconi M, Govoni V, De Vito A, et al. Restless legs syndrome and pregnancy. Neurology 2004;63(6):1065-9
23. O'Keeffe ST, Gavin K, Lavats JN. Iron status and restless legs syndrome in the elderly. Age Ageing 1994;23(3):200-3
24. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 2001;18(2):128-47
25. Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol 2005;4(8):465-75
26. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 2004;5(4):385-91
27. Garcia-Borreguero D, Larrosa O, Granizo JJ, et al. Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome. Sleep 2004;27(4):669-73
28. Baier PC, Trenkwalder C. Circadian variation in restless legs syndrome. Sleep Med 2007;8(6):645-50
29. Earley CJ, Hyland K, Allen RP. Circadian changes in CSF dopaminergic measures in restless legs syndrome. Sleep Med 2006;7(3):263-8
30. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999;52(5):932-7
31. Ruottinen HM, Partinen M, Hublin C, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000;54(2):502-4
32. Eisensehr I, Wetter TC, Linke R, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001;57(7):1307-9
33. Tribl GG, Asenbaum S, Happe S, et al. Normal striatal D2 receptor binding in idiopathic restless legs syndrome with periodic leg movements in sleep. Nucl Med Commun 2004;25(1):55-60
34. Allen RP, Barker PB, Wehrl F, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001;56(2):263-5
35. Earley CJ, Barker P, Horská A, Allen RP. MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome. Sleep Med 2006;7(5):458-61
36. Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003;61(3):304-9
37. Sun ER, Chen CA, Ho G, et al. Iron and the restless legs syndrome. Sleep 1998;21(4):371-7
38. Earley CJ, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000;54(8):1698-700
39. Ondo WG, Zhao HR, Le WD. Animal models of restless legs syndrome. Sleep Med 2007;8(4):344-8
40. Winkelmann J, Ferini-Strambi L. Genetics of restless legs syndrome. Sleep Med Rev 2006;10(3):179-83
41. Winkelmann J, Polo O, Provini F, et al. Genetics of restless legs syndrome (RLS): State-of-the-art and future directions. Mov Disord 2007;22(S18):449-58
42. Winkelmann J, Wetter TC, Collado-Seidel V, et al. Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep 2000;23(5):597-602
43. Walters AS, Hickey K, Maltzman J, et al. A questionnaire study of 138 patients with restless legs syndrome: the 'Night-Walkers' survey. Neurology 1996;46(1):92-5
44. Bassetti CL, Mauerhofer D, Gugger M, et al. Restless legs syndrome: a clinical study of 55 patients. Eur Neurol 2001;45(2):67-74
45. Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med 2000;1(1):11-9
46. Pichler I, Marroni F, Volpato CB, et al. Linkage analysis identifies a novel locus for restless legs syndrome on chromosome 2q in a South Tyrolean population isolate. Am J Hum Genet 2006;79(4):716-23
47. Desautels A, Turecki G, Montplaisir J, et al. Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. Arch Neurol 2005;62(4):591-6
48. Levchenko A, Montplaisir JY, Dubé MP, et al. The 14q restless legs syndrome locus in the French Canadian population. Ann Neurol 2004;55(6):887-91
49. Chen S, Ondo WG, Rao S, et al. Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet 2004;74(5):876-85
50. Levchenko A, Provost S, Montplaisir JY, et al. A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13. Neurology 2006;67(5):900-1
51. Stefansson H, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007;357(7):639-47
52. Winkelmann JW. Periodic limb movements in sleep - endophenotype for restless legs syndrome? N Engl J Med 2007;357(7):703-5
53. Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007;39(8):1000-6
54. Xiong L, Dion P, Montplaisir J, et al. Molecular genetic studies of DMT1 on 12q in French-Canadian restless legs syndrome patients and families. Am J Med Genet B Neuropsychiatr Genet 2007;144(7):911-7
55. Chesson AL Jr, Wise M, Davila D, et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 1999;22(7):961-8
56. Hening W, Allen R, Earley C, et al. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep 1999;22(7):970-99
57. Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004;79(7):916-22
58. Vignatelli L, Billiard M, Clarenbach P, et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006;13(10):1049-65
59. Oertel WH, Trenkwalder C, Zucconi M, et al. State of the art in restless legs syndrome therapy: Practice recommendations for treating restless legs syndrome. Mov Disord 2007;22(S18):466-75
60. Hening WA, Allen RP, Earley CJ, et al. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004;27(3):560-83
61. García-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007;8(5):520-30
62. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19(3):205-13
63. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356(1):29-38
64. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356(1):39-46
65. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006;67(7):1225-9
66. Dewey RB 2nd, Reimold SC, O'Suilleabhain PE. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. Arch Neurol 2007;64(3):377-80
67. Ropinirole hydrochloride prescribing information, 2005. Available from: http://us.gsk.com/products/assets/us_requip.pdfREQUIP [Last accessed 7 February 2008]
68. Trenkwalker C, García-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75(1):92-7
69. Walters AS, Ondo WG, Dreykluft T, et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004;19(12):1414-23
70. Bogan RK, Fry JM, Schmidt MH, et al. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006;81(1):17-27
71. Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004;27(5):907-14
72. Montplaisir J, Karrasch J, Haan J, Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord 2006;21(10):1627-35
73. Lee D, Earl N. Long-term tolerability of ropinirole in Restless Legs Syndrome (RLS): results from two 52-week studies. J Am Geriatr Soc 2006;54(s4):S54;A101
74. Dreykluft T, García-Borreguero D, Lee D. Long-term safety and efficacy of ropinirole in moderate-to-severe RLS: results of two 52-week, open-label studies. Eur J Neurol 2005;12 Suppl 2:96; P1244
75. Dreykluft T, Karrasch J, Smuts J, et al. The long-term safety and tolerability of ropinirole in RLS. Mov Disord 2004;19 Suppl 9:S430-1
76. Walters AS, Lebrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4(2):121-32
77. Ferguson EA. Ropinirole CR - a new extended-release formulation - reduces symptom severity in patients with primary restless legs syndrome (RLS). Neurology 2007;68(12 Suppl 1):A255
78. Becker EA. Ropinirole CR - a new extended release formulation - demonstrates onset of symptom improvement from the first night of treatment in patients with moderate-to-severe primary restless legs syndrome (RLS). Sleep 2007;30:A285
79. Ferguson EA. Ropinirole CR extended release demonstrates improvements from the first night of treatment in patients with moderate-to-severe primary restless legs syndrome (RLS). Neurology 2007;68(12 Suppl 1):A256
80. Bogan EA. Ropinirole CR - extended release - reduces sleep disturbance in patients with moderate-to-severe primary restless legs syndrome: results from a 12-week, randomized, double-bind, placebo-controlled study. Sleep 2007;30:A285
81. Schmidt EA. A novel extended-release formulation - ropinirole CR - improves quality of life in patients with moderate-to-severe primary restless legs syndrome: results from a 12-week pivotal trial. Sleep 2007;30:A289
82. Ziman EA. Ropinirole CR - an extended-release formulation - improves quality of life in patients with moderate-to-severe primary restless legs syndrome (RLS): results from a 12-week pivotal study. Neurology 2007;68(12 Suppl 1):A256
83. Siddiqui F, Strus J, Ming X, et al. Rise of blood pressure with periodic limb movements in sleep and wakefulness. Clin Neurophysiol 2007;118(9):1923-30
84. Trenkwalder C, Paulus W. Why do restless legs occur at rest? Pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2). Clin Neurophysiol 2004;115(9):1975-88
85. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000;39(4):243-54